Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of July 4, 2026, GILD trades at $131.27 with a market cap of $162.98B and a P/E ratio of 17.69. GILD moved +4.18% today. Year to date, GILD is +6.95%; over the trailing twelve months it is +17.72%. Its 52-week range spans $86.08 to $157.29. Analyst consensus is strong buy with an average price target of $160.37. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Gilead Sciences (GILD) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. GILD moved +4.18% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $131.27 |
| Market Cap | $162.98B |
| P/E Ratio | 17.69 |
| EPS | $7.42 |
| Dividend Yield | 0.82% |
| 52-Week High | $157.29 |
| 52-Week Low | $86.08 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $29.74B |
| Net Income | $9.22B |
| Gross Margin | 79.36% |
22 analysts cover GILD: 0 strong buy, 19 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $160.37.